Skip to main content

Search

Reset all filters
635 Result(s)
Sort by

Ridgefield

Ridgefield

Ridgefield is home to the company’s US headquarters. The site serves as a key research center for human pharmaceuticals.
Avian influenza prevention at the source

Avian influenza prevention at the source

Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Phase 3 studies survodutide obesity and overweight

Phase 3 studies survodutide obesity and overweight

Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
Combination Therapy

Combination Therapy

It’s the smart combination of our cancer cell-directed and immuno-oncology approaches that may offer the greatest benefit for people living with cancer.
Be green Japan

Be green Japan

Boehringer Ingelheim's Yamagata site is gradually switching to a more sustainable energy supply.
Outside the lab…inside the family

Outside the lab…inside the family

We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
Rewards and recognition

Rewards and recognition

There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Martin Stefanic

Martin Stefanic

Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
How dangerous is the mpox virus?

How dangerous is the mpox virus?

Mpox, formerly known as monkeypox: What exactly is this virus, how is it transmitted, and what are the most noticeable symptoms?
Our Vision

Our Vision

At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
Brigitte Fuhr

Brigitte Fuhr

Brigitte Fuhr, our Head of Central Data Science, joined our team to make millions of lives better. Now she’s working on a global program that will transform our ability to develop ground-breaking treatments.
Cooperation with The Defeat-NCD Partnership

Cooperation with The Defeat-NCD Partnership

Together with The Defeat-NCD Partnership, Boehringer Ingelheim aims to address key access to healthcare issues related to non-communicable diseases.
Practical Advice

Practical Advice

Practical advice for people with type 2 diabetes (T2D) at risk of heart disease
Bowel Issues

Bowel Issues

Find out how to handle changes to bowel habits following cancer treatment from Taking Cancer On Through Flavour
Strategic-collaboration-with-EnaraBio

Strategic-collaboration-with-EnaraBio

Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.